Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-T rollover osimertinib continuation study
2022-501528-58-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of osimertinib in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoint: Serious adverse events and serious adverse events of special interest. Planned start Oct 2023; status: authorised.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-501528-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501528-58-00.